{
    "organizations": [],
    "uuid": "783d23ba290d16d071d372beb153b03af90c68c4",
    "author": "Reuters Editorial",
    "url": "https://www.reuters.com/article/brief-ligand-pharma-signs-license-agreem/brief-ligand-pharma-signs-license-agreement-idUSFWN1QO0Q1",
    "ord_in_thread": 0,
    "title": "BRIEF-Ligand Pharma Signs License Agreement",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "March 6 (Reuters) - Ligand Pharmaceuticals Inc:\n* LIGAND PHARMACEUTICALS INC - SIGNED LICENSE AGREEMENT GRANTING ROIVANT SCIENCES EXCLUSIVE GLOBAL RIGHTS TO DEVELOP AND COMMERCIALIZE LGD-6972 Source text for Eikon: Further company coverage:\n ",
    "published": "2018-03-07T05:38:00.000+02:00",
    "crawled": "2018-03-07T19:40:15.006+02:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "march",
        "reuters",
        "ligand",
        "pharmaceutical",
        "inc",
        "ligand",
        "pharmaceutical",
        "inc",
        "signed",
        "license",
        "agreement",
        "granting",
        "roivant",
        "science",
        "exclusive",
        "global",
        "right",
        "develop",
        "commercialize",
        "source",
        "text",
        "eikon",
        "company",
        "coverage"
    ]
}